A completely new drug in the ‘gliptin’ family has disrupted the anti-diabetes market by lowering the cost of therapy for patients by 80%. With the launch of the teneligliptin molecule, the popular ...

MUMBAI: In a move that could potentially disrupt the anti-diabetes drug market in India and lead to a price war, Ahmedabad based Zydus Cadila on Friday said it launched its brand Tenglyn, pricing it ...

BARCELONA, Spain — New data from EXAMINE, the cardiovascular-safety trial with the type 2 diabetes drug alogliptin (Nesina, Takeda Pharmaceuticals), has shown no significantly increased risk for heart ...

Ahmedabad-based Zydus Cadila is launching an anti-diabetic drug teneligliptin at an aggressive price of Rs 7 per day, almost 1/6th the price at which gliptins were initially launched in India.

India's Zydus Cadila could be about to shake up the India market for diabetes drugs with its Nov. 20 launch of Tenglyn (teneligliptin) for controlling hypoglycemia associated with the Type 2 version ...

A new analysis suggests GLP 1 receptor agonists, the diabetes drugs that include semaglutide, dulaglutide and liraglutide, may be linked with a modestly lower risk of developing epilepsy in people ...

MUMBAI: A new anti-diabetes drug from the ‘gliptin’ family soon to be launched in India promises to lower treatment cost for patients by 55-60%. The launch of ‘Teneligliptin’ by Mumbai-based Glenmark ...

At least two key drugs in the gliptin category have already gone off patent and cheaper variants are crowding the market. Also, several patent expiries are round the corner for the newest category of ...

The new trials were conducted to fulfill the 2008 US Food and Drug Administration (FDA) requirement for cardiovascular safety studies in all diabetes drugs — prompted at the time by widely publicized ...

With all the controversy surrounding the long-term side effects of anti-diabetic drugs, diabetologists have decided to put in extra effort to ensure that benefits overweigh the risks when they ...

About 50 major manufacturing companies in India are planning to launch combinations of the anti-diabetic drug sitagliptin either with metformin or dapagliflozin in the Indian market very soon. With ...

A new study published in the journal Neurology is reporting an association between a particular class of drugs used to treat type 2 diabetes and decreased Alzheimer's disease biomarkers. It is unclear ...